Ivy Foundation Funds Diabetes Program


Ivy Foundation Funds Diabetes Intervention

Posted By  on July 22, 2013

Catherine Ivy and St Vincent de PaulThe Ben & Catherine Ivy Foundation (Ivy Foundation) announced its funding of the Family Wellness Program managed by the Society of St. Vincent de Paul, Phoenix. The Ivy Foundation is the largest privately funded brain cancer research foundation in North America; Catherine Ivy is the founder and president of the Ivy Foundation.

The Family Wellness Program is a culturally responsive diabetes intervention program which provides education, lifestyle improvement skills, medical, and counseling services to adults, children, and their families who have been diagnosed with diabetes and pre-diabetes and its associated comorbidities (two or more medical conditions present simultaneously in a patient). The overall goal is to empower these families with the knowledge, tools and skills to make health a priority throughout their lives.

Specific program objectives include:

  • Affecting lifestyle choices in food, fitness, and self-efficacy that enhance and establish ongoing positive health behaviors;
  • Increasing knowledge and skills in recognizing, managing and improving risk factors, disease, and quality of life throughout the life span;
  • Measuring health changes through objective and subjective instruments.
  • Evaluating effectiveness of and fine-tuning the model using community- based participatory research;
  • Responding to the increasing need for intervention by developing competent professionals who can replicate the model throughout the community.

“While we typically only fund brain cancer research programs, we knew the impact of this program was so strong and the need so great in our local community that we chose to support it,” said Ivy. “We also learn from the research of other diseases and this gives us a fresh perspective.”

“There is proven success with this program. The majority of participants have demonstrated significant improvements in their health as seen in laboratory markers. Patients are healthier. They come back as alumni to attend classes in order to receive continued social support for their lifestyle changes from program staff, volunteers and fellow participants,” said Society of St. Vincent de Paul, Phoenix, Executive Director Steve Zabilski. “We are grateful to the Ivy Foundation for their support of this high-impact program.”



TGen President Speaks at Brookings Institution Biomedical Conference

TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference

Dr. Trent presents TGen’s precision medicine research at the world’s most influential think tank

Dr Jeffrey Trent Outside TGen

TGen President and Research Director Dr. Jeffrey Trent speaks at Brookings Institution

WASHINGTON, D.C. – July 15, 2013 – Dr. Jeffrey Trent, President and Research Director for the Translational Genomics Research Institute (TGen), will discuss state-of-the-art genomics research July 16 at the Brookings Institution.

Dr. Trent, Ph.D., F.A.C.M.G., and former Scientific Director of the National Human Genome Research Institute, is part of a panel, Innovation in Action, at Brookings’ 2nd annual State of Biomedical Innovation Conference, which will focus on the use of novel data sources to improve medical product development and care delivery.

Specifically, Dr. Trent will discuss TGen’s ongoing work in translating genomics research into clinical benefit. TGen is one of a very few centers who are using the entire human genome in clinical trials in order to diagnose or make treatment decisions for an individual patient (precision medicine).

“The human genome will be the medical textbook for the next century and beyond,” Dr. Trent said. “By harnessing the power of the human genome, we will provide immeasurable patient benefit while at the same time reducing the time and costs of diagnosis and treatment. TGen is a global leader in clinical trials that deploy this form of innovative research.”

TGen’s translational model enables pioneering discoveries in the laboratory to be quickly moved to clinical trials where they can be used to immediately benefit patients with many types of cancer and other debilitating diseases.

Dr. Trent’s panel will be moderated by Dr. Mark B. McClellan, Director and Fellow of Brookings’ Initiative on Innovation and Value in Health Care. He is the former administrator for the Centers for Medicare and Medicaid Services (2004-2006), and the former commissioner of the Food and Drug Administration (2002-2004). He also served as a member of the President’s Council of Economic Advisers, and as senior director for health care policy at the White House (2001-2002). In these positions, he developed and implemented major reforms in health policy.

This conference is being convened by the Engelberg Center for Health Care Reform at Brookings, which was established to help turn ideas for health care reform into action, including reducing gaps in insurance coverage and ensuring health care affordability. Its mission is to develop data-driven, practical policy solutions that promote broad access to high-quality, affordable and innovative care in the United States. The Center also conducts research, makes policy recommendations, and facilitates development of new consensus around key issues, providing technical support to implement and evaluate new solutions in collaboration with a broad range of stakeholders.

The conference is scheduled for 9 a.m.-12:30 p.m. EDT July 16 at the Brookings Institution, Falk Auditorium, 1775 Massachusetts Avenue, N.W., Washington, D.C.  Dr. Trent’s hour-long panel is scheduled to start at 10:10 a.m.  The event will be streamed live on the Brookings website: http://www.brookings.edu/events/2013/07/16-biomedical-innovation.

About the Brookings Institution
The Brookings Institution is a nonprofit public policy organization based in Washington, DC. Our mission is to conduct high-quality, independent research and, based on that research, to provide innovative, practical recommendations that advance three broad goals: strengthen American democracy; foster the economic and social welfare, security and opportunity of all Americans; and secure a more open, safe, prosperous and cooperative international system. Brookings is proud to be consistently ranked as the most influential, most quoted and most trusted think tank. More information: www.brookings.edu.

About TGen
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.


Scientists Use a New Strategy for Brain Cancer Treatment

Brain-penetrating particle attacks deadly tumors

Jul 02, 2013 by Eric Gershon

Brain-penetrating particle attacks deadly tumors

(Phys.org) —Scientists have developed a new approach for treating a deadly brain cancer that strikes 15,000 in the United States annually and for which there is no effective long-term therapy. The researchers, from Yale and Johns Hopkins, have shown that the approach extends the lives of laboratory animals and are preparing to seek government approval for a human clinical trial.

“We wanted to make a system that would penetrate into the brain and deliver drugs to a greater volume of tissue,” said Mark Saltzman, a biomedical engineer at Yale and principal investigator of the research. “Drugs have to get to tumor cells in order to work, and they have to be the right drugs.”

Results were published July 1 in the Proceedings of the National Academy of Sciences.

Glioblastoma multiforme is a malignant cancer originating in the brain. Median survival with standard care—surgery plus chemotherapy plus radiation—is just over a year, and the five-year survival rate is less than 10 percent.

Current methods of drug delivery have serious limitations. Oral and intravenously injected drugs have difficulty accessing the brain because of a biological defense known as the blood-brain barrier. Drugs released directly in the brain through implants can’t reach migrating tumor cells. And commonly used drugs fail to kill the cells primarily responsible for tumor development, allowing regrowth.

The researchers developed a new, ultra-small drug-delivery particle that more nimbly navigates brain tissue than do existing options. They also identified and tested an existing FDA-approved drug—a fungicide called dithiazanine iodide (DI)—and found that it can kill the most aggressive tumor-causing cells.

“This approach addresses limitations of other forms of therapy by delivering drugs directly to the area most needed, obviating systemic side-effects, and permitting the drug to reside for weeks,” said neurosurgeon Dr. Joseph M. Piepmeier, a member of the research team. Piepmeier leads clinical research for Yale Cancer Center’s brain tumor program.

The drug-loaded nanoparticles are administered in fluid directly to the brain through a catheter, bypassing the blood-brain barrier. The particles’ tiny size—their diameter is about 70 nanometers—facilitates movement within brain tissue. They release their drug load gradually, offering sustained treatment.

In tests on laboratory rats with human brain cancers, DI-loaded nanoparticles significantly increased median survival to 280 days, researchers report. Maximum median survival time for rats treated with other therapies was 180 days, and with no treatment, survival was 147 days. Tests on pigs established that the new drug-particle combination also diffuses deep into brains of large animals.

The nanoparticles are made of polymers, or strings of repeating molecules. Their size, ability to control release, and means of application help them permeate brain tissues.

Researchers screened more than 2,000 FDA-approved drugs in the hunt for candidates that would kill the cells most responsible for human tumor development, brain cancer stem cells. Overall, DI worked best.

The scientists believe the particles can be adapted to deliver other drugs and to treat other central nervous system diseases, they said.

Read more at: http://phys.org/news/2013-07-brain-penetrating-particle-deadly-tumors.html#jCp

See How Some People Are Honoring Zach’s Memory…


Ryan Woods was diagnosed with Glioblastoma and told he had 1-4 months to live. He decided to let his story be heard. SoulPancake helped his voice be heard by the world. Share in his story… his love… and his inspiration. Take his story and allow it to inspire you to make a difference on this earth!

Ryan Woods passed away on Nov. 7, 2012. Our thoughts and prayers are with his wife and children. Thank you for sharing your story with us, Ryan. We will miss you.

More from SoulPancake:
Follow us on Facebook: http://facebook.com/SoulPancake
Tweet us at: http://twitter.com/SoulPancake


View original post

Watch Dr. Sam Gambhir of Stanford University

Dr. Sam Gambhir of Stanford University says the support of the Ben and Catherine Ivy Foundation allows for multi-center trials to research Glioblastoma brain tumors.

Betty Hayden is Back to Pruning Roses After Fighting Rare Brain Cancer

After Brain Cancer Battle, Orange County, CA, Resident Picks Up Active Life Where She Left Off

Released: 5/31/2013 8:00 PM EDT
Source Newsroom: Cedars-Sinai Medical Center

Newswise — LOS ANGELES (June 3, 2013) – Westminster resident Betty Hayden loves to work in her yard and looks forward to traveling on weekends to dog shows with her daughter. But the retired school employee’s active lifestyle came to a halt last June with the sudden appearance of aggressive brain tumors.

After the diagnosis, Hayden’s daughter, Tammy Porter, expected doctors to quickly create a coordinated treatment plan. When they didn’t, she contacted brain cancer specialists at Cedars-Sinai Medical Center, where Hayden was evaluated and hospitalized within days. A year later, the cancer is in remission and Hayden is back in action, tending to her yard a couple of hours a day.

“In my opinion, they saved my mom’s life because they worked so fast to get us in,” said Porter, who first noticed changes in Hayden’s behavior during a weekend dog show in Ventura.

“She was going to bed really early, which isn’t like her,” Porter said. ”My mom can run circles around everyone else, but she was going to bed at 7 o’clock and sleeping a lot. She just wasn’t 100 percent herself. She was walking a little to the left, and I noticed that when she was talking, she sometimes would throw in a word that was kind of out of left field,” said Porter, who looks out for her mom who lives alone after being widowed about 10 years ago. They made an appointment for Hayden to see her doctor as soon as they got home.

Hayden’s behavior at the brief doctor’s visit was normal and blood tests were negative. But, Porter, convinced something wasn’t right, asked if a brain scan could be done.

“After the CAT scan, I got a call from the doctor, saying, ‘Your mom has two masses in her brain. You need to get to an emergency department ASAP,” Porter said, adding that her mother, 72, has always been fit, healthy and active. A biopsy found that the masses in her brain were cancerous.

“That was just horrible. I got the call and sat down with her and told her. … It’s amazing how something you don’t even know about just all of a sudden changes your life,” Porter said.

Hayden said the doctor seemed indifferent: “I said, ‘Now what do we do?’ And the doctor said, ‘We’re finished. You have to go see another doctor.’”

But Porter, believing her mother needed medical attention sooner rather than later, grew frustrated with the doctors’ apparent lack of interest, urgency and follow-up. As she tried desperately to reach unavailable doctors, she asked a friend to search the Internet for other options. The name of Keith L. Black, MD, chair of the Department of Neurosurgery at Cedars-Sinai, came up, and Porter sent an email to James Villalobos, RN, program development coordinator, in the department.

“It was about 9 o’clock on a Saturday night and I emailed Dr. Black’s office, not expecting, of course, to hear from them until Monday. But that’s when James called back. He called me back that night, at 9 o’clock. I was amazed,” Porter recalled, adding that she was even more impressed when Villalobos arranged coordinated consultations at Cedars-Sinai a few days later.

She and her mother met with neurosurgeon Chirag Patil, MD, director of the Center for Neurosurgical Outcomes Research, and neuro-oncologist Jeremy Rudnick, MD, a brain cancer expert in the Department of Neurology and the Department of Neurosurgery. Because Hayden’s cancer was not amenable to surgery, Rudnick took the lead.

“He looked at her MRIs and started telling us about this disease,” Porter recalled. “He said, ‘I’d like to get you in right now. This is a fast-growing cancer.’ He showed us her MRI pictures. This was the first time we had seen them. Her brain center line was totally out of skew. Her brain had so much swelling because of the tumors it’s amazing she didn’t have more side effects.”

Rudnick said Hayden’s cancer, central nervous system lymphoma, a type of non-Hodgkin lymphoma, is so rare that a general hospital may see a case only once every five years; Cedars-Sinai doctors treat 10 or 20 patients a year. It’s considered a stage 4 lymphoma, one of the most aggressive forms of the disease.

“With this disease, we can see a doubling of tumor in just weeks. Betty was declining quickly but she and her daughter weren’t getting the information or help they needed. The day after we saw her we had her in the hospital getting high-dose IV chemotherapy,” Rudnick said, adding that Cedars-Sinai has several treatment options for the disease, including an aggressive and potentially curative high-dose chemotherapy/stem cell transplant protocol.

Hayden underwent a more standard regimen: a weeklong hospital stay for chemotherapy every other week for four or five months.

“If she had gone much longer without treatment, I don’t know that she would have survived. But she responded beautifully and her disease is in remission. She had a response in all the tumors and right now her MRIs are completely clean and clear. She’s doing remarkably well, pruning the rose bushes and going to dog shows,” Rudnick said. “For me, that’s incredibly rewarding.”


Check Out Ivy Foundation in AZ Business Magazine!


Posted on May 20, 2013 by News Release

prevention trial - brain scan images

The Ben & Catherine Ivy Foundation (Ivy Foundation) announced its 2012 grant recipients, which total more than $9 million in funding for brain cancer research. The Ivy Foundation is the largest privately funded brain cancer research foundation in North America. Catherine Ivy is the founder and president of the Ivy Foundation, which has a research funding focus on glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adults.

The Ivy Foundation awarded the following grants and/or provided funding in 2012:

· $2,500,000 over three years:  Principal Investigator, Greg D. Foltz, M.D., Director, The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center
· $5,000,000 over five years:  Principal Investigators, John Carpten, Ph.D. and David Craig, Ph.D., Translational Genomics Research Institute (TGen) – a collaborative effort with University of California, San Francisco; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; Dana Farber/Harvard Cancer Center; MD Anderson; and University of Utah
· $45,000 annually: Principal Investigator, Brandy Wells, Translational Genomics Research Institute (TGen), for the Ivy Neurological Sciences Internship program
· Over $2 million paid out in 2012 for previously committed multi-year brain cancer research grants

“We are encouraged and remain strongly committed to moving the progress forward for patients diagnosed with brain cancer,” said Ivy. “The 2012 Ivy Foundation grant recipients are important strategic partners in our objective to double the life expectancy of people diagnosed with GBM within the next seven years.”


Tarik Massoud Joins Stanford University School of Medicine

Tarik Massoud
Date added: April 22, 2013photo of Tarik Massoud
Submission Type: New Hire
Current employer: Stanford University School of Medicine and Medical Centre
Current title/position: Professor of radiology and molecular imaging
Industry: Health Care
Position department:Medical and Science
Duties/responsibilities:Tarik Massoud has been hired as a professor of radiology and molecular imaging by the Stanford University School of Medicine and Medical Center, based in Stanford.


Tarik Massoud joins Stanford University School of Medicine to build and direct new initiative for brain cancer research, funded by Ivy Foundation.